Lilly files six lawsuits in bid to shut down ‘black market’ for retatrutide

Ahead of an approval filing, the drugmaker is amping up a fight against sellers who claim to offer versions of its highly anticipated “triple-G” weight loss medicine.

By Kristin Jensen • Aug. 12, 2026

Regulatory operations: The overlooked half of submission readiness

Submission readiness extends beyond content. Early regulatory operations planning supports a compliant, high-quality application.

Aug. 10, 2026

Explore the Trendline➔

Commercialization

New drugs for obesity are becoming blockbusters, while Trump administration pressure is reshaping pharma marketing strategies ahead of looming patent cliffs.

By BioPharma Dive staff

Erica Schwartz confirmed as next CDC director

Schwartz will step into an agency that has been without a permanent leader for almost a year amid RFK Jr.’s tumultuous tenure as HHS chief. 

By Kristin Jensen • Aug. 6, 2026

Lilly climbs, Novo falls as obesity drug battle intensifies

A research disappointment and a miss on Wegovy pill sales hurt Novo, while Lilly’s injectable franchise once again surpassed analyst expectations.

By Kristin Jensen • Aug. 5, 2026

Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch

Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.

By Delilah Alvarado , Ben Fidler • Aug. 5, 2026

FTC sues Hims & Hers over alleged privacy violations, deceptive billing practices

Regulators say the telehealth company illegally shared patients’ health data with advertisers and misled its customers. Hims & Hers hit back, calling the claims “baseless.”

By Jill Hughes • July 30, 2026

Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology push

Better-than-expected sales helped Biogen regain the support of investors, while AstraZeneca and GSK worked to convince Wall Street that they can hit ambitious revenue targets.

By BioPharma Dive staff • July 29, 2026

[Podcast] (Season 2) The Progress Profile: Alzheimer’s Research in Focus

This podcast explores how leading Alzheimer’s experts are working to bridge the gap between clinical trial design and frontline care.

By BioPharma Dive's studioID • July 27, 2026

Novo sues Lilly, alleging ‘misleading’ advertising of obesity drugs

The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are broadly superior to Novo’s medicines. Lilly countered that its campaign is “truthful.”

By Jonathan Gardner • July 21, 2026

Novartis climbs on upbeat drug sales as key readouts loom

A return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger impact on the company’s long-term outlook.

By Kristin Jensen • July 21, 2026

Compounders maintain a firm grip on the GLP-1 market

Despite an FDA crackdown, numerous pharma lawsuits and possible safety risks, nearly 1 in 5 patients are still taking cheaper weight-loss alternatives.

By Kelly Bilodeau • July 17, 2026

On second try, Acadia drug gets nod from European regulators

The influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the marketing authorization for Tavneos be revoked.

By Jonathan Gardner • June 26, 2026

Hospitals irate after Eli Lilly follows through on 340B ultimatum

The drugmaker stopped paying 340B discounts to hospitals that didn’t comply with its new paperwork requirements late last week. Hospitals are urging HRSA to step in.

By Rebecca Pifer Parduhn • June 23, 2026

From episodes to a lifetime: How AI can enable women’s health brands to build a partnership that lasts

Women's health audiences have long memories and finely tuned instincts for what is performative.

By Jennifer M. Barrett, MSc • June 22, 2026

Medicare drug price rule may target under-the-skin Keytruda and Opdivo

For 2029, a federal rule proposes closing a "loophole" that protects medicines transitioning from intravenous administration from price protection.

By Jonathan Gardner • June 15, 2026

Generic drugmakers gain key victory in ‘skinny label’ patent case

The Supreme Court ruled that a knockoff version of Amarin’s Vascepa didn’t infringe on patents — a decision with far-reaching implications for the availability of generics.

By Jonathan Gardner • June 5, 2026

Eli Lilly issues data sharing ultimatum to 340B hospitals

Select hospitals have refused to share data to prove they’re not double-dipping drug discounts, Lilly said. Hospitals, which have until Monday to comply, are urging the government to intervene.

By Rebecca Pifer Parduhn • June 2, 2026

CVS obesity drug deal puts Lilly on equal footing with Novo

The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk. 

By Kristin Jensen • May 28, 2026

FDA asks Lilly to evaluate obesity pill’s liver risk

The request, which is part of a just-released approval letter for Foundayo, comes amid an intensifying marketing battle between Lilly and Novo.

By Jonathan Gardner • April 15, 2026

J&J leans on Tremfya, cancer drugs to overcome Stelara losses

A growing multiple myeloma franchise helped the pharmaceutical giant top Wall Street’s expectations and surpass $15 billion in first-quarter drug sales.

By Jonathan Gardner • April 14, 2026

Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk

After winning the battle for injectable obesity medicines, Lilly hopes Foundayo can help it catch up in the oral market, where Novo has a three-month lead.

By Kristin Jensen • April 9, 2026

Hims & Hers says limited data stolen in social engineering attack

The telehealth provider said hackers gained access to a third-party customer service platform, but medical records remained secure.

By David Jones • April 6, 2026

FDA approves Lilly obesity pill, triggering battle with Novo Nordisk

Foundayo could erase the Wegovy pill’s four-month head start as the two drugmakers clash on a debate of efficacy and convenience.

By Jonathan Gardner • April 1, 2026

New FDA guidance could elevate pharma’s biosimilar market

Biologic copycats have had a limited impact on U.S. drug prices so far, but loosening regulatory restrictions could help accelerate their progress. 

By Michael Gibney • March 13, 2026

Lilly warns GLP-1 knockoffs may be ‘dangerous,’ escalating war with compounders

Lilly asked the FDA to step in after claiming that testing it’s done suggests copycat versions of Zepbound may carry “unknown risks.”

By Jonathan Gardner • March 12, 2026